07:00 , Jul 11, 2011 |  BC Week In Review  |  Company News

Apricus Biosciences, BioTox Sciences deal

Apricus (formerly known as NexMed Inc. ) sold its Bio-Quant Inc. subsidiary to CRO BioTox for $5 million, plus up to $20 million over 10 years based on BioTox's projected revenues. Bio-Quant is a drug...
08:00 , Dec 21, 2009 |  BC Week In Review  |  Company News

Bio-Quant Inc., NexMed deal

NexMed completed its previously announced acquisition of drug discovery company Bio-Quant in a stock and note deal valued at about $13.4 million based on NexMed's close of $0.32 on Dec. 11, the last trading day...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Company News

Bio-Quant, NexMed deal

NexMed will acquire drug discovery company Bio-Quant in a stock and note deal valued at about $12.8 million. NexMed will issue 4 million new shares valued at $680,000, based on NexMed's close of $0.17 on...
08:00 , Dec 5, 2005 |  BC Week In Review  |  Company News

MicroIslet scientific advisory board update

MicroIslet Inc. (MII), San Diego, Calif.   Business: Metabolic, Gene/Cell therapy   Appointed: Bassam Damaj, president and CEO at Bio-Quant Inc.; Athanassios Sambanis, professor of chemical engineering at the Georgia Institute of Technology; and Nora...
08:00 , Dec 17, 2001 |  BC Week In Review  |  Company News

Bio-Quant Inc., Dompe S.p.A. deal

The companies will identify drug candidates against four chemokine receptors, including IL-8, related to inflammatory and immune diseases, such as atherosclerosis, glomerulonephritis, asthma and allergy. Bio-Quant will use its G protein-coupled receptor high throughput screening...
08:00 , Dec 10, 2001 |  BC Extra  |  Company News

Bio-Quant, Dompe chemokine deal

The companies will identify drug candidates against four chemokine receptors, including IL-8, related to inflammatory and immune diseases, such as atherosclerosis, glomerulonephritis, asthma and allergy. Bio-Quant (San Diego, Calif.) will use its G protein-coupled receptor...
07:00 , Oct 8, 2001 |  BC Week In Review  |  Company News

Bio-Quant Inc., TEF Labs deal

The companies will develop dyes for use in HTS assays. The deal combines Bio-Quant's Fluorescence Infrared Bioluminescence Reader and ChemoReader imaging device with TEF's chemistry. Bio-Quant Inc. , San Diego, Calif.   TEF Labs ,...